Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR T790M-negative”

15 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 15 of 15 results

Not applicableUnknownNCT04116918
What this trial is testing

Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC

Who this might be right for
NSCLC Stage IVEGFR T790M-negativeAnlotinib+1 more
Baodong Qin 100
Testing effectiveness (Phase 2)Study completedNCT03513666
What this trial is testing

Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment

Who this might be right for
NSCLC
Shanghai Junshi Bioscience Co., Ltd. 40
Testing effectiveness (Phase 2)Ended earlyNCT02454842
What this trial is testing

Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients

Who this might be right for
Non-small Cell Lung CancerNSCLCNon-squamous NSCLC
Rain Oncology Inc 21
Testing effectiveness (Phase 2)Study completedNCT03758287
What this trial is testing

Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative

Who this might be right for
Non-small Cell Lung Cancer
Sunshine Lake Pharma Co., Ltd. 108
Testing effectiveness (Phase 2)Study completedNCT02489903
What this trial is testing

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Who this might be right for
Small Cell CarcinomaCarcinoma, Non-Small-Cell LungNeuroendocrine Tumors+1 more
EpicentRx, Inc. 139
Large-scale testing (Phase 3)UnknownNCT01579630
What this trial is testing

Genius Study Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Stage IV EGFR Mutation Negative or T790M Single Mutation Who Respond to Pemetrexed/ Platinum as First-line Therapy

Who this might be right for
NSCLC
Taipei Veterans General Hospital, Taiwan 52
Post-approval studies (Phase 4)Active Not RecruitingNCT04413201
What this trial is testing

AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLC

Who this might be right for
Non-squamous NSCLC
Michael Hopp 34
Testing effectiveness (Phase 2)UnknownNCT04338243
What this trial is testing

Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors

Who this might be right for
Negative T790M Mutation and Met Amplification
Haihe Biopharma Co., Ltd. 70
Early research (Phase 1)Study completedNCT03516214
What this trial is testing

EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations

Who this might be right for
Bronchial Neoplasms
University of Cologne 18
Testing effectiveness (Phase 2)Ended earlyNCT02323126
What this trial is testing

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Novartis Pharmaceuticals 64
Testing effectiveness (Phase 2)UnknownNCT03706287
What this trial is testing

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Who this might be right for
Lung Cancer Metastatic
Sichuan Cancer Hospital and Research Institute 62
Testing effectiveness (Phase 2)UnknownNCT03765775
What this trial is testing

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

Who this might be right for
CarcinomaNon-small Cell Lung CancerLung Neoplasm
First Hospital of Shijiazhuang City 20
Large-scale testing (Phase 3)Ended earlyNCT04816214
What this trial is testing

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 6
Testing effectiveness (Phase 2)UnknownNCT03389256
What this trial is testing

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Who this might be right for
Lung DiseasesNeoplasmsRespiratory Tract Diseases+2 more
Sichuan Cancer Hospital and Research Institute 144
Testing effectiveness (Phase 2)UnknownNCT06277674
What this trial is testing

Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI

Who this might be right for
Non-small Cell Lung Cancer
Guangzhou University of Traditional Chinese Medicine 20